BOULDER, CO — InDevR, a Boulder-based life science company, announced today that it has signed a contract (HHSO100201400010C) with the Biomedical Advanced Research and Development Authority (BARDA) to complete product development of their unique influenza diagnostic, FluChip-8G, which is capable of rapidly genotyping influenza viruses directly from clinical samples. The total contract award is for […]

ALAMEDA, Calif. — BioTime, Inc. (NYSE MKT: BTX) announced that its subsidiary Asterias Biotherapeutics, Inc. (OTCBB: ASTY) has reached an agreement with Cancer Research UK and Cancer Research Technology (CRT), the charity’s development and commercialization arm, to conduct a clinical trial of Asterias’ novel immunotherapy treatment AST-VAC2 in subjects with non-small cell lung cancer. AST-VAC2 […]

On September 11, 2014, BGI, Imperial College London and Waters Corporation signed a framework agreement in Shenzhen, China. Liangyu Zhang, CEO of Greater China of Waters Corporation, Vince Gao, CEO of BGI Heath, and representatives of Imperial College London attended the signing ceremony. The collaboration brings together three of the leading scientific groups in the […]

BOSTON & SEATTLE & HOUSTON & NEW YORK & SAN DIEGO — World-renowned cancer centers and Illumina, Inc. (NASDAQ:ILMN) today announced the formation of the Actionable Genome Consortium (AGC), an effort to recommend openly published standards for the widespread use of next-generation sequencing to guide decision-making in clinical oncology. The core remit of the AGC […]

Rockland Immunochemicals received a $224,473 SBIR grant from the NIH’s National Heart Lung and Blood Institute to develop an antibody-based point-of-care device that can diagnose sickle cell disease. Rockland says it secured the award by demonstrating the technology’s ability to develop and produce life science tools for basic and clinical research focused on functional genomics […]

Cambridge UK — Abcam plc, a global leader in the manufacture and supply of innovative protein research tools and services, and Cell Marque Corporation, a provider of antibodies and reagents for diagnostic immunohistochemistry, announced today they have signed a global 10-year strategic marketing agreement for Abcam’s in vitro diagnostic (IVD) immunohistochemistry (IHC) RabMAb® primary antibody […]

CINCINNATI — Meridian Bioscience Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced it has signed a new agreement with Premier, Inc. to offer the complete illumigene® molecular menu of tests to its members. Premier serves more than 3,000 U.S. hospitals and 110,000-plus other healthcare sites. This agreement offers each Premier healthcare facility the opportunity to implement rapid, […]

SUNNYVALE, Calif.– Cepheid (NASDAQ: CPHD) today announced the release of Xpert® TV, an on-demand molecular test for rapid, accurate and reproducible identification of Trichomoniasis (TV) infections in both males and females. The test will be marketed as a CE-IVD product under the European Directive on In Vitro Diagnostic Medical Devices, bringing the total number of […]

Shortly after receiving ISO 13485 accreditation, Sophia Genetics has become the first European company to obtain a CE-IVD mark for the clinical use of an Next Generation Sequencing (NGS) bioinformatic pipeline for routine genetic testing. This quality assurance certification represents an important step in raising the standards of routine genetic testing and clinical diagnosis, and […]

SUNNYVALE, Calif.– Cepheid (NASDAQ: CPHD) announced today the release of Xpert® Flu/RSV XC, an on-demand molecular test for rapid, accurate and reliable determination of Flu A, Flu B, and differentiation of RSV infection. The test will be marketed as a CE-IVD product under the European Directive on In Vitro Diagnostic Medical Devices, bringing the total […]